ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
38.22
0.03%
US Tech 100
19,287.60
-0.24%
S&P 500
5,702.55
-0.19%
US Dollar vs CAD
1.35775
0.00%
Bitcoin
63,099.21
-0.44%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Tevogen Bio Holdings Inc (TVGN) Share Price

Tevogen Bio Holdings Inc

Tevogen Bio Holdings Inc (TVGN)

NASDAQ
0.46
0.02
(4.55%)
Closed September 21 3:00PM
Delayed by 15 minutes
0.4462
-0.0138
(-3.00%)
After Hours: 5:56PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
0.4462
Bid
0.425
Ask
0.4777
Volume
372,213
0.424 Day's Range 0.466
0.40 52 Week Range 21.09
Market Cap
76.143M
Previous Close
0.44
Open
0.44
Last Trade
10
@
0.4777
Last Trade Time
Financial Volume
US$ 163,373
VWAP
0.438924
Average Volume (3m)
226,414
Shares Outstanding
170,646,864
Dividend Yield
-
PE Ratio
-1,125.00
Earnings Per Share (EPS)
-0
Revenue
-
Net Profit
-67k

About Tevogen Bio Holdings Inc

Tevogen Bio is a leading NextGen clinical-stage specialty immunotherapy Biotech developing off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Tevogen Bio is a leading NextGen clinical-stage specialty immunotherapy Biotech developing off-the-shelf precision T cell therapeutics in virology, oncology, and neurology.

Sector
Biological Pds,ex Diagnstics
Industry
Blank Checks
Website
www.tevogen.com/
Headquarters
Wilmington, Delaware, USA
Founded
2024
Tevogen Bio Holdings Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker TVGN. The last closing price for Tevogen Bio was US$0.44. Over the last year, Tevogen Bio shares have traded in a share price range of US$ 0.40 to US$ 21.09.

Tevogen Bio currently has 170,646,864 shares outstanding. The market capitalization of Tevogen Bio is US$75.08 million. Tevogen Bio has a price to earnings ratio (PE ratio) of -1125.00.

Ask ADVFN Intelligence (AI)

TVGN Latest News

More News

Form 424B3 - Prospectus [Rule 424(b)(3)]

August 26 2024
Edgar (US Regulatory)

Form 8-K/A - Current report: [Amend]

August 26 2024
Edgar (US Regulatory)

Form 424B3 - Prospectus [Rule 424(b)(3)]

August 23 2024
Edgar (US Regulatory)

Form 8-K - Current report

August 23 2024
Edgar (US Regulatory)

Tevogen Bio Secures $6 Million Series C Preferred Stock Investment

WARREN, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing...

August 22 2024
GlobeNewswire Inc.

CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares

WARREN, N.J., Aug. 15, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Tevogen Bio Inc (Nasdaq: TVGN), please note that paragraph two has been updated. The...

August 15 2024
GlobeNewswire Inc.

Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares

WARREN, N.J., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing...

August 15 2024
GlobeNewswire Inc.

Form 424B3 - Prospectus [Rule 424(b)(3)]

August 14 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

August 14 2024
Edgar (US Regulatory)

Tevogen Bio’s Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health

WARREN, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holding Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing...

August 14 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0365-7.561632483940.48270.5130.41531457520.46125095CS
4-0.1778-28.49358974360.6240.62730.41659760.46580915CS
12-0.2938-39.70270270270.740.840.42264140.59480554CS
26-4.1838-90.36285097194.634.780.46555431.51765086CS
52-3.6538-89.11707317074.121.090.45585131.57039583CS
156-3.6538-89.11707317074.121.090.45585131.57039583CS
260-3.6538-89.11707317074.121.090.45585131.57039583CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BNZIBanzai International Inc
US$ 5.645
(96.01%)
61.39M
ZJYLJin Medical International Ltd
US$ 3.975
(50.00%)
1.24M
ANEBAnebulo Pharmaceuticals Inc
US$ 2.9001
(39.43%)
78.85k
XPONExpion360 Inc
US$ 0.081
(39.18%)
1.46B
AENTAlliance Entertainment Holding Corporation
US$ 2.74
(34.31%)
4.23M
GSIWGarden Stage Ltd
US$ 1.34
(-82.89%)
26.44M
CRBPCorbus Pharmaceuticals Holdings Inc
US$ 19.51
(-62.26%)
12.29M
LGCBLinkage Global Inc
US$ 0.4183
(-57.70%)
2.16M
BFIBurgerFi International Inc
US$ 0.0855
(-42.27%)
15.05M
SKYESkye Bioscience Inc
US$ 3.17
(-42.26%)
5.14M
XPONExpion360 Inc
US$ 0.081
(39.18%)
1.46B
NVDANVIDIA Corporation
US$ 116.00
(-1.59%)
378.16M
AAPLApple Inc
US$ 228.20
(-0.29%)
320.24M
INTCIntel Corporation
US$ 21.84
(3.31%)
261.68M
VERBVerb Technology Company Inc
US$ 0.0742
(33.45%)
178.65M

TVGN Discussion

View Posts
Monksdream Monksdream 2 months ago
TVGN new 52 week low
👍️0
ChuckPaul63 ChuckPaul63 4 months ago
Corporate overview: Robust and IMPRESSIVE drug pipeline. (tevogen.com) $TVGN.
👍️ 1
harry crumb harry crumb 4 months ago
Pour souls on this scam
👍️0
glenn1919 glenn1919 4 months ago
TVGN.............................https://stockcharts.com/h-sc/ui?s=TVGN&p=W&b=5&g=0&id=p86431144783
👍️0
Invest-in-America Invest-in-America 4 months ago
TVGN: Up 52% in the Post-M right now behind last Friday's (Post-M) PR --- behind circa 15-mil. shares Float. Said (Post-Close) Friday news elaborated that they secured $51-mil. financing. Also, some recent April 2024 news about no more circa $91-mil. "liability" to worry about. (Whelp, not exactly a CURE for Cancer, so far, nor any of the many diseases they are targeting; but appears they are getting their MONEY in good order.)
https://www.globenewswire.com/news-release/2024/05/10/2879865/0/en/Tevogen-Bio-Announces-Up-to-50-Million-in-Financing-to-Further-Advance-Operational-Objectives.html (This identical PR was splattered over many, many, news media sites.)
👍️0
tw0122 tw0122 5 months ago
Jump jump
👍️0
Monksdream Monksdream 5 months ago
TVGN SPAC junk new 52 lo

👍️0
2020trader 2020trader 5 months ago
TVGN down 12% today, expecting lower
👍️0
Monksdream Monksdream 5 months ago
SPAC junk
👍️0
2020trader 2020trader 6 months ago
down 17% today
👍️0
2020trader 2020trader 6 months ago
expecting lower
👍️0
Monksdream Monksdream 6 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc
👍️0
Monksdream Monksdream 6 months ago
Will it grow legs after 9:30
https://ih.advfn.com/markets/nasdaq/premarket
👍️0
Monksdream Monksdream 6 months ago
Tevogen Bio Holdings Inc NASDAQ: TVGN

GoSymbol lookup
Health Care : Biotechnology | Company profile
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, is an off-the-shelf, allogeneic cytotoxic CD8+ T cell therapy designed to fill a critical gap in COVID-19 therapeutic solutions for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. In addition to TVGN 489, it has several product candidates under early-stage development. The Company is developing Epstein-Barr virus (EBV) specific CTLs for potential use in multiple sclerosis (MS) and EBV-associated lymphomas. Its TVGN 601 is being developed for MS, and its TVGN 930 is being developed for EBV-associated lymphomas.
👍️0

Your Recent History

NASDAQ
TVGN
Tevogen Bio
BIT
F17245
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved